Leishmaniose visceral em adolescente gestante

Vieira, Maria Luisa de Sá; Jacobina, Ronaldo Ribeiro; Soares, Neci Matos

doi:10.9771/cmbio.v6i3.4398

Cited by 4 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An explanation is given by Veloso et al [21], when they describe that ACL can reach individuals of any age, being more frequent from 20 to 40 years. Other researchers corroborating the findings are Vieira, Jacobina and Soares [22], who describe that the highest concentration of cases of ACL is in the most productive age group (15-60) of age and in the male gender. Still, according to the same authors, this factor is related to the occupational character of this endoepidemic.…”

Section: Resultssupporting

confidence: 57%

Untitled

2018

IJAERS

View full text Add to dashboard Cite

American Cutaneous Leishmaniasis (ACL) is one of the parasites with specific characteristics in several regions of Brazil. In recent years, there have been variations in the increase in the number of cases of this disease in different regions of the country. In the state of Rondônia, ACL is considered one of the endemic diseases. Objective: This study described epidemiological aspects of ACL in a subspace of Rondônia, Western Amazon, in the period between 2012 and 2013. Method: This is a retrospective epidemiological study developed in 02 municipalities located in the south of Rondônia according to with model developed by comprising the municipalities of Vilhena and Chupinguaia. Results: The study revealed that 370 human cases of ACL were reported in the study period. The male gender predominated with (89.5%) of the total cases, the age range (20 to 39) years (36.6%) prevailed, low schooling (80%) had a maximum of complete elementary education (62.5%). The greatest number of cases came from the urban zone (66.9%), resulting from the adaptation of sandflies to the periurbanization of cities in the Amazon, as predicted by . Some of these variables presented significant differences when compared to production and distribution in the

show abstract

Section: Resultssupporting

confidence: 57%

Untitled

2018

IJAERS

View full text Add to dashboard Cite

show abstract

“…Untreated (n = 3; 2001-2017). Three cases of VL identified during pregnancy were untreated [25,65,66]. Treatment was deferred until after delivery due to safety concerns in one report in a mother in third trimester [25]; there were signs of intra-uterine growth retardation requiring an emergency C-section, and both mother and the child were alive.…”

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

“…Treatment was deferred until after delivery due to safety concerns in one report in a mother in third trimester [25]; there were signs of intra-uterine growth retardation requiring an emergency C-section, and both mother and the child were alive. The second mother in third trimester was not treated due to lack of adequate hospital resources [65]; the baby born to the mother died after 2 months due to malnutrition with no evidence of vertical transmission. In the third case, VL was diagnosed but the mother died after giving birth and before treatment could be administered [66]; the baby also died and foetal part placenta examination revealed presence of Leishman Donovan bodies by polymerase chain reaction indicating vertical transmission.…”

Section: Plos Neglected Tropical Diseasesmentioning

confidence: 99%

Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans

et al. 2021

View full text Add to dashboard Cite

Background Reports on the occurrence and outcome of Visceral Leishmaniasis (VL) in pregnant women is rare in published literature. The occurrence of VL in pregnancy is not systematically captured and cases are rarely followed-up to detect consequences of infection and treatment on the mother and foetus. Methods A review of all published literature was undertaken to identify cases of VL infections among pregnant women by searching the following database: Ovid MEDLINE; Ovid Embase; Cochrane Database of Systematic Reviews; Cochrane Central Register of Controlled Trials; World Health Organization Global Index Medicus: LILACS (Americas); IMSEAR (South-East Asia); IMEMR (Eastern Mediterranean); WPRIM (Western Pacific); ClinicalTrials.gov; and the WHO International Clinical Trials Registry Platform. Selection criteria included any clinical reports describing the disease in pregnancy or vertical transmission of the disease in humans. Articles meeting pre-specified inclusion criteria and non-primary research articles such as textbook, chapters, letters, retrospective case description, or reports of accidental inclusion in trials were also considered. Results The systematic literature search identified 272 unique articles of which 54 records were included in this review; a further 18 records were identified from additional search of the references of the included studies or from personal communication leading to a total of 72 records (71 case reports/case series; 1 retrospective cohort study; 1926–2020) describing 451 cases of VL in pregnant women. The disease was detected during pregnancy in 398 (88.2%), retrospectively confirmed after giving birth in 52 (11.5%), and the time of identification was not clear in 1 (0.2%). Of the 398 mothers whose infection was identified during pregnancy, 346 (86.9%) received a treatment, 3 (0.8%) were untreated, and the treatment status was not clear in the remaining 49 (12.3%). Of 346 mothers, Liposomal amphotericin B (L-AmB) was administered in 202 (58.4%) and pentavalent antimony (PA) in 93 (26.9%). Outcomes were reported in 176 mothers treated with L-AmB with 4 (2.3%) reports of maternal deaths, 5 (2.8%) miscarriages, and 2 (1.1%) foetal death/stillbirth. For PA, outcomes were reported in 88 mothers of whom 4 (4.5%) died, 24 (27.3%) had spontaneous abortion, 2 (2.3%) had miscarriages. A total of 26 cases of confirmed, probable or suspected cases of vertical transmission were identified with a median detection time of 6 months (range: 0–18 months). Conclusions Outcomes of VL treatment during pregnancy is rarely reported and under-researched. The reported articles were mainly case reports and case series and the reported information was often incomplete. From the studies identified, it is difficult to derive a generalisable information on outcomes for mothers and babies, although reported data favours the usage of liposomal amphotericin B for the treatment of VL in pregnant women.

show abstract

“…Three cases of VL identified during pregnancy were untreated [12,55,56]. Treatment was deferred until after delivery due to safety concerns in one study [12]; there were signs of intra-uterine growth retardation requiring emergency C-section, and both mother and the child were alive.…”

Section: Resultsmentioning

confidence: 99%

“…Treatment was deferred until after delivery due to safety concerns in one study [12]; there were signs of intra-uterine growth retardation requiring emergency C-section, and both mother and the child were alive. The second mother was not treated due to lack of adequate hospital resources [55]; the baby born to the mother died after 2 months due to malnutrition with no evidence of vertical transmission. In the third case, VL was diagnosed but the mother died after giving birth and before treatment could be administered [56]; the baby also died and foetal part placenta examination revealed presence of Leishman Donovan bodies by PCR indicating vertical transmission.…”

Section: Resultsmentioning

confidence: 99%

Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans

Dahal

Singh-Phulgenda

Maguire

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Reports on the occurrence and outcome of Visceral Leishmaniasis (VL) in pregnant women is rare in published literature. The occurrence of VL in pregnancy is not systematically captured and cases are rarely followed-up to detect consequences of infection and treatment on the mother and foetus. Methods: A review of all published literature was undertaken to identify cases of VL infections during pregnancy by searching the following database: Ovid MEDLINE; Ovid Embase; Cochrane Database of Systematic Reviews; Cochrane Central Register of Controlled Trials; World Health Organization Global Index Medicus: LILACS (Americas); IMSEAR (South-East Asia); IMEMR (Eastern Mediterranean); WPRIM (Western Pacific); ClinicalTrials.gov; and the WHO International Clinical Trials Registry Platform. Selection criteria included any clinical reports describing the disease in pregnancy or vertical transmission of the disease in humans. Articles meeting pre-specified inclusion criteria and non-primary research articles such as textbook, chapters, letters, retrospective case description, or reports of accidental inclusion in trials were also considered. Results: We screened 272 publications and identified a total of 70 records (1926-2020) describing 447 VL cases in pregnant women. The disease was detected during pregnancy in 394 (88.1%), retrospectively confirmed after giving birth in 52 (11.6%), and the time of identification was not clear in 1 (0.2%). Of the 394 mothers whose infection was identified during pregnancy, 344 (89.1%) received a treatment, 3 (0.8%) were untreated, and the treatment status was not clear in the remaining 47 (12.2%). Of 344 mothers, Liposomal Amphotericin B (L-AmB) was administered in 202 (58.7%) and pentavalent antimony (PA) in 92 (26.7%). Outcomes were reported in 176 mothers treated L-AmB with 4 (2.3%) reports of maternal deaths, 5 (2.8%) miscarriages, and 2 (1.1%) foetal death/stillbirth. For PA, outcomes were reported in 87 mothers of whom 4 (4.6%) died, 24 (27.6%) had spontaneous abortion, 2 (2.3%) had miscarriages. A total of 26 cases of confirmed, probable or suspected cases of vertical transmission were identified and the median time to detection was 6 months (range: 0-18 months). Conclusions: Outcomes of VL treatment during pregnancy is rarely reported and under-researched. When it is reported, information is often incomplete and it is difficult to derive generalisable information on outcomes for mothers and babies, although reported data favours the usage of liposomal amphotericin B for the treatment of VL in pregnant women.

show abstract

Leishmaniose visceral em adolescente gestante

Cited by 4 publications

References 13 publications

Untitled

Untitled

Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans

Visceral Leishmaniasis in pregnancy and vertical transmission: A systematic literature review on the therapeutic orphans

Contact Info

Product

Resources

About